HER2DX检测对早期HER2阳性乳腺癌患者病理反应和预后的预测价值：对PHERGain试验的评论 - Suppr

The predictive value of HER2DX assay with pathological response and prognosis in patients with early HER2-positive breast cancers: commentary on the PHERGain trial.

作者信息

Matsuoka Tasuku, Yamamoto Yurie, Yashiro Masakazu

机构信息

Department of Molecular Oncology and Therapeutics, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.

Institute of Medical Genetics, Osaka Metropolitan University, Osaka, Japan.

出版信息

Transl Cancer Res. 2025 Mar 30;14(3):1507-1510. doi: 10.21037/tcr-2024-2421. Epub 2025 Mar 20.

DOI:10.21037/tcr-2024-2421

PMID:40224980

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11985196/

Abstract

摘要

相似文献

The predictive value of HER2DX assay with pathological response and prognosis in patients with early HER2-positive breast cancers: commentary on the PHERGain trial.

Transl Cancer Res. 2025 Mar 30;14(3):1507-1510. doi: 10.21037/tcr-2024-2421. Epub 2025 Mar 20.

HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial.

Clin Cancer Res. 2024 Sep 13;30(18):4123-4130. doi: 10.1158/1078-0432.CCR-24-0464.

HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers.

ESMO Open. 2025 Feb;10(2):104100. doi: 10.1016/j.esmoop.2024.104100. Epub 2025 Jan 17.

Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer.

EBioMedicine. 2022 Jan;75:103801. doi: 10.1016/j.ebiom.2021.103801. Epub 2022 Jan 3.

HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial.

EBioMedicine. 2022 Nov;85:104320. doi: 10.1016/j.ebiom.2022.104320. Epub 2022 Oct 29.

A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.

Lancet Oncol. 2020 Nov;21(11):1455-1464. doi: 10.1016/S1470-2045(20)30450-2.

Application and challenge of HER2DX genomic assay in HER2+ breast cancer treatment.

Am J Cancer Res. 2024 Sep 15;14(9):4218-4235. doi: 10.62347/JWHA6355. eCollection 2024.

HER2DX genomic test in early-stage HER2-positive breast cancer.

ESMO Open. 2024 Dec;9(12):103987. doi: 10.1016/j.esmoop.2024.103987. Epub 2024 Nov 16.

Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab.

JAMA Oncol. 2023 Jun 1;9(6):835-840. doi: 10.1001/jamaoncol.2023.0181.

Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network-Breast dataset (SCAN-B).

ESMO Open. 2024 Mar;9(3):102388. doi: 10.1016/j.esmoop.2024.102388. Epub 2024 Mar 4.

本文引用的文献

A Comprehensive Analysis of Neoadjuvant Chemotherapy in Breast Cancer: Adverse Events, Clinical Response Rates, and Surgical and Pathological Outcomes-Bozyaka Experience.

Cancers (Basel). 2025 Jan 7;17(2):163. doi: 10.3390/cancers17020163.

Evaluation of tumor infiltrating lymphocytes as a prognostic biomarker in patients with ductal carcinoma in situ of the breast.

Breast Cancer Res Treat. 2024 Nov;208(1):9-18. doi: 10.1007/s10549-024-07466-9. Epub 2024 Aug 24.

HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial.

Clin Cancer Res. 2024 Sep 13;30(18):4123-4130. doi: 10.1158/1078-0432.CCR-24-0464.

Breast Cancer Screening and Prevention.

Ann Intern Med. 2023 Nov;176(11):ITC161-ITC176. doi: 10.7326/AITC202311210. Epub 2023 Nov 14.

Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.

Ann Oncol. 2023 Sep;34(9):783-795. doi: 10.1016/j.annonc.2023.05.012. Epub 2023 Jun 9.

Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab.

JAMA Oncol. 2023 Jun 1;9(6):835-840. doi: 10.1001/jamaoncol.2023.0181.

Deciphering breast cancer: from biology to the clinic.

Cell. 2023 Apr 13;186(8):1708-1728. doi: 10.1016/j.cell.2023.01.040. Epub 2023 Mar 16.

The complex nature of heterogeneity and its roles in breast cancer biology and therapeutic responsiveness.

Front Endocrinol (Lausanne). 2023 Feb 23;14:1083048. doi: 10.3389/fendo.2023.1083048. eCollection 2023.

HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial.

EBioMedicine. 2022 Nov;85:104320. doi: 10.1016/j.ebiom.2022.104320. Epub 2022 Oct 29.

Neoadjuvant pertuzumab in non-metastatic HER2-positive breast tumors: Multicentric study in Peru (NeoHer).

Mol Clin Oncol. 2022 Mar;16(3):70. doi: 10.3892/mco.2022.2503. Epub 2022 Jan 25.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

The predictive value of HER2DX assay with pathological response and prognosis in patients with early HER2-positive breast cancers: commentary on the PHERGain trial.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献